Gastroenterology
Volume 134, Issue 2 , Pages 405-415, February 2008

Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach

  • Jean–Michel Pawlotsky

      Affiliations

    • French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Henri Mondor Hospital, University of Paris XII, Créteil, France
    • INSERM U841, Créteil, France
    • Corresponding Author InformationAddress requests for reprints to: Jean-Michel Pawlotsky, MD, PhD, Department of Virology, Hopital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. fax: (33) 1-4981-4831.
    • ,
  • Geoffrey Dusheiko

      Affiliations

    • Centre for Hepatology, Royal Free and University College School of Medicine, London, United Kingdom
    • ,
  • Angelos Hatzakis

      Affiliations

    • Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece
    • ,
  • Daryl Lau

      Affiliations

    • Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • George Lau

      Affiliations

    • Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    • ,
  • T. Jake Liang

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Stephen Locarnini

      Affiliations

    • Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    • ,
  • Paul Martin

      Affiliations

    • Division of Liver Diseases and Recanati-Miller Transplant Institute, Mount Sinai School of Medicine, New York, New York
    • ,
  • Douglas D. Richman

      Affiliations

    • VA San Diego Healthcare System and University of California San Diego, La Jolla, California
    • ,
  • Fabien Zoulim

      Affiliations

    • INSERM U871, Hospices Civils de Lyon, Department of Liver Diseases, Université Lyon 1, Lyon, France

Received 16 February 2007; accepted 1 November 2007. published online 29 November 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported in part by the VIRGIL European Network of Excellence on Antiviral Drug Resistance, by a grant (LSHM-CT-2004-503359) from the Priority 1 “Life Sciences, Genomics and Biotechnology for Health” program in the 6th Framework Program of the European Union, and by the French National Agency for AIDS and Viral Hepatitis Research (ANRS) (J.M.P. and F.Z.); in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (T.J.L.); and in part by the Extramural Research Program of the National Institutes of Health (RO-1: AIO60449 to S.L.).

 Jean-Michel Pawlotsky acted as a consultant/advisor for Roche (Basel, Switzerland), Gilead (Foster City, CA), Bristol-Myers Squibb (Princeton, NJ), Idenix (Cambridge, MA), and Novartis (Basel, Switzerland), and received research support from Roche and Gilead; Geoffrey Dusheiko received consultancy fees from Glaxo SmithKline (London, UK), Roche, Novartis, Schering Plough (Kenilworth, NJ), Idenix, Gilead Sciences, and Bristol-Myers Squibb, and received research support from the same groups; Daryl Lau acted as a consultant/advisor and has received research grants from Roche, Gilead, Bristol-Myers Squibb, and Novartis; George Lau is a Consultant for Roche and Novartis; Stephen Locarnini has received royalties and is a patent holder for Melbourne Health (Parkville, Victoria, Australia), has received consulting fees from Evivar (Melbourne, Victoria, Australia), Gilead, Pharmasset, and Bristol-Myers Squibb, has received research support from Evivar and Gilead, and has ownership interests in Pharmasset (Princeton, NJ); Paul Martin is a consultant and speaker for Bristol-Myers Squibb, Gilead, Idenix, and Roche; Douglas D. Richman is a consultant for Bristol-Myers Squibb, Gilead, Idenix, and Roche; and Fabien Zoulim is a consultant and has received speaker fees from Gilead, Bristol-Myers Squibb, Idenix, and Novartis.

PII: S0016-5085(07)02113-0

doi:10.1053/j.gastro.2007.11.036

Refers to article:

  • Continuing Medical Education Exam 2: February 2008

    Gastroenterology February 2008 (Vol. 134, Issue 2, Page 596)

Gastroenterology
Volume 134, Issue 2 , Pages 405-415, February 2008

Article Tools